Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have undergone a heart transplantation and who receive their routine care at the Morgan Stanley Children's Hospital of New York, Columbia University Medical Center~Exclusion Criteria:~* Patients admitted to the inpatient heart failure team~* Patients present for their first outpatient catheterization after new transplant~* Abnormal hemodynamics concerning for acute rejection~* Patients present for follow up of rejection (last biopsy positive)~* Ingested methylxanthine-containing foods that day~* Patients taking oral dipyridamole and did not discontinue it 3 days prior to testing~* Prior transplant history of coronary artery vasculopathy with this allograft or concern for abnormal coronary vasculature by angiography on the day of the catheterization~* Patients taking carbamazepine (may potentiate adenosine effect)~* Patients with known conduction disease (first, second or third degree atrioventricular block) and/or with pre-existing sinus node dysfunction (based on pre-existing ECG, Holter or inpatient telemetry)~* Patients/guardians unable to give consent in English

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine (Type: EXPERIMENTAL): After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).